Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02075957

Acronym

SITRR

Enrollment

192

Registered

2014-03-03

Start date

2013-10-31

Completion date

2016-06-30

Last updated

2014-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

Non-small cell lung cancer, adjuvant chemo-therapy, DNA chip

Brief summary

Description of new transcriptional profiles associated with risk of relapse and identification of specific sites of relapse in non-small cell lung cancer, toxicity and resistance to adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC).

Detailed description

* A first blood sample will be taken during the week before the operation. A second blood sample will be taken 4 to 8 weeks after the operation. And in case of relapse, a third sample will be taken. These samples are going to be stored in the collection of biological resources of Angers. * Concerning the biopsy of the resected NSLCL, it will be sent to the collection of biological resources of Angers for conservation directly next to the surgery.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Major subject * Subject who received resection with primary non-small cell lung cancer at the University Hospital of Angers and whose tumor samples will be stored in collection of biological resources of University Hospital of Angers * A written inform consent.

Exclusion criteria

* Under 18 year old; * Pregnant or nursing women; * Deprived of liberty; * Age under curatorship or guardianship; * Unable to consent person; * About not carrying a non-small cell lung cancer.

Design outcomes

Primary

Measure	Time frame	Description
Determination of news microarrays profiles of NSCLC relapse risks	6 to 8 weeks after surgery	The news microarrays profiles of NSCLC relapse risks will : * assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) * assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient * assessing the prediction of sites most likely metastatic relapse to guide survey strategy.

Countries

France

Contacts

Primary ContactJosé HUREAUX, Doctor

johureaux@chu-angers.fr241353678

Backup ContactAmandine AULNETTE, CRA

amandine.aulnette@chu-angers.fr241358015

Outcome results